sun_ranbaxy_investor_presentation (1) - Creating the Worlds 5th Largest Specialty Generic Pharma Company Sun Pharma Ranbaxy Merger April 7 2014

sun_ranbaxy_investor_presentation (1) - Creating the Worlds...

This preview shows page 1 - 5 out of 20 pages.

Creating the World’s 5 th Largest Specialty Generic Pharma Company Sun Pharma – Ranbaxy Merger – April 7, 2014
Image of page 1
2 Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Sun Pharmaceutical Industries Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Creating the World's 5 th Largest Specialty Generic Co - Sun Pharma - Ranbaxy Merger
Image of page 2
3 Creating the World’s 5 th Largest Specialty Generic Pharma Company ° 5 th largest global specialty generic pharma company ° No. 1 pharma company in India, one of the fastest growing markets ° No. 1 Indian pharma company in US market ° Over US$ 2 billion in sales ° Pipeline of 184 ANDAs including high-value FTFs ° No. 1 in generic dermatology, No. 3 in branded ° Approaching US$ 1 billion sales in high-growth emerging markets ° Expanding presence in Western Europe CY 2013 pro forma Revenues – US$ 4.2 bn Creating the World's 5 th Largest Specialty Generic Co - Sun Pharma - Ranbaxy Merger
Image of page 3
4 Transaction Highlights ± Sun Pharma to acquire Ranbaxy ² Ranbaxy shareholders to get 0.8 shares of Sun Pharma stock for every share of Ranbaxy ± Deal size approximately US$ 4 billion; ~ 2.2x LTM sales ± US$ 250 million of revenue and operating synergies by 3rd year post close ± Daiichi-Sankyo to become the second largest shareholder in Sun Pharma. Strategic business relationship to continue with Sun Pharma ± Voting Agreements ² Daiichi-Sankyo to vote in favor of transaction (~63.5% ownership) ² Sun Pharma promoters to vote in favor of transaction (~63.7% ownership) Creating the World's 5 th Largest Specialty Generic Co - Sun Pharma - Ranbaxy Merger
Image of page 4
Image of page 5

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture